1. Home
  2. JQC vs NRIX Comparison

JQC vs NRIX Comparison

Compare JQC & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JQC
  • NRIX
  • Stock Information
  • Founded
  • JQC 2003
  • NRIX 2009
  • Country
  • JQC United States
  • NRIX United States
  • Employees
  • JQC N/A
  • NRIX 286
  • Industry
  • JQC Finance Companies
  • NRIX Biotechnology: Pharmaceutical Preparations
  • Sector
  • JQC Finance
  • NRIX Health Care
  • Exchange
  • JQC Nasdaq
  • NRIX Nasdaq
  • Market Cap
  • JQC 765.7M
  • NRIX 750.4M
  • IPO Year
  • JQC N/A
  • NRIX 2020
  • Fundamental
  • Price
  • JQC $5.18
  • NRIX $9.85
  • Analyst Decision
  • JQC
  • NRIX Strong Buy
  • Analyst Count
  • JQC 0
  • NRIX 15
  • Target Price
  • JQC N/A
  • NRIX $29.13
  • AVG Volume (30 Days)
  • JQC 714.6K
  • NRIX 1.3M
  • Earning Date
  • JQC 01-01-0001
  • NRIX 10-09-2025
  • Dividend Yield
  • JQC 11.13%
  • NRIX N/A
  • EPS Growth
  • JQC N/A
  • NRIX N/A
  • EPS
  • JQC N/A
  • NRIX N/A
  • Revenue
  • JQC N/A
  • NRIX $83,687,000.00
  • Revenue This Year
  • JQC N/A
  • NRIX $78.20
  • Revenue Next Year
  • JQC N/A
  • NRIX N/A
  • P/E Ratio
  • JQC N/A
  • NRIX N/A
  • Revenue Growth
  • JQC N/A
  • NRIX 48.32
  • 52 Week Low
  • JQC $4.82
  • NRIX $8.18
  • 52 Week High
  • JQC $5.65
  • NRIX $29.56
  • Technical
  • Relative Strength Index (RSI)
  • JQC 35.81
  • NRIX 53.67
  • Support Level
  • JQC $5.17
  • NRIX $8.20
  • Resistance Level
  • JQC $5.35
  • NRIX $10.87
  • Average True Range (ATR)
  • JQC 0.07
  • NRIX 0.59
  • MACD
  • JQC -0.00
  • NRIX 0.22
  • Stochastic Oscillator
  • JQC 25.42
  • NRIX 61.87

About JQC Nuveen Credit Strategies Income Fund Shares of Beneficial Interest

Nuveen Credit Strategies Income Fund is a diversified closed-end management investment company. Its investment objective is to provide high current income and total return. The fund meets its investment objectives by investing its managed assets in senior secured and second lien loans, and its managed assets across the capital structure of companies (including equity securities) with a primary emphasis on high yield bonds, convertible securities and other forms of income-producing securities.

About NRIX Nurix Therapeutics Inc. Common stock

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

Share on Social Networks: